# Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis

> **NCT00317499** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 205 (actual)

## Conditions studied

- Psoriatic Arthritis
- Psoriasis

## Interventions

- **OTHER:** Placebo
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00317499
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2002-06
- **Final completion:** 2002-07
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2010-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317499, "Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00317499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*